Pfizer (PFE) Subsequent Tender Offer for Icagen (ICGN) Expires
Tweet
Share
E-mailGet Alerts PFE Hot Sheet
Join SI Premium – FREE
Pfizer Inc. (NYSE: PFE) and Icagen, Inc. (Nasdaq: ICGN) announced today the expiration of the subsequent offering period of the cash tender offer by Pfizer’s wholly-owned subsidiary, Eclipse Acquisition Corp., for all of the outstanding shares of common stock of Icagen for $6.00 per share, paid to the seller in cash, without interest thereon, less any applicable withholding and transfer taxes.
The subsequent offering period expired at 6:00 p.m., New York City time, on Monday, September 19, 2011.
The subsequent offering period expired at 6:00 p.m., New York City time, on Monday, September 19, 2011.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Real and RE/MAX Holdings receive court approval for merger
- Cytek faces $56M damages award in Beckman Coulter patent case
- enVVeno Medical (NVNO) files $100M mixed shelf
Create E-mail Alert Related Categories
Corporate News, Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
